We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-1.62%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.99B
AUM Growth
-$546M
Cap. Flow
-$71.8M
Cap. Flow %
-2.4%
Top 10 Hldgs %
48.59%
Holding
90
New
10
Increased
29
Reduced
22
Closed
16
Avg Time Held Equity + Options
1.3 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
1.2 years
Avg Time Held Equity only
1.3 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
1.2 years

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$131M
2
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$75.7M
3
IGMS icon
IGM Biosciences
IGMS
+$63.5M
4
ALLK icon
Allakos
ALLK
+$51.3M
5
NVRO icon
NEVRO CORP.
NVRO
+$48.5M

Top Sells

Rank Stock Value
1
ARRY icon
Array Biopharma Inc
ARRY
+$405M
2
EHTH icon
eHealth
EHTH
+$76.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$62.6M
4
ELV icon
Elevance Health
ELV
+$51.8M
5
UNH icon
UnitedHealth
UNH
+$34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Miscellaneous 0.93%
3 Energy 0.01%
4 Technology 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FTSV
51
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$10.4M 0.35%
1,627,498
+1,393,498
+596% +$11.4M
2019 Q2
1 quarter
VAPO
52
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$9.09M 0.3%
119,942
– –
2018 Q4
3 quarters
GTHX icon
53
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$8.9M 0.3%
390,934
+98,200
+34% +$3.1M
2019 Q2
1 quarter
CBIO icon
54
Crescent Biopharma
CBIO
$452M
$8.61M 0.29%
19,976
-108
-0.5% -$69.5K
2017 Q2
9 quarters
LOGC
55
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$8.1M 0.27%
749,026
-65,872
-8% -$705K
2018 Q4
3 quarters
CMRX icon
56
DELISTED
Chimerix, Inc.
CMRX
$7.6M 0.25%
3,235,795
-322,593
-9% -$931K
2016 Q2
13 quarters
SDC
57
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$6.81M 0.23%
+490,340
New +$8.18M
2019 Q3
0 quarters
GOSS icon
58
Gossamer Bio
GOSS
$54.3M
$4.37M 0.15%
3,256
+148
+5% +$235K
2019 Q1
2 quarters
HZNP
59
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$400K 0.01%
14,700
+3,300
+29% +$85.3K
2019 Q2
1 quarter
OVID icon
60
Ovid Therapeutics
OVID
$432M
$395K 0.01%
121,950
-615,600
-83% -$1.4M
2017 Q2
9 quarters
MYOK
61
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$375K 0.01%
7,182
+930
+15% +$49.5K
2018 Q2
5 quarters
ELGX
62
DELISTED
Endologix Inc
ELGX
$313K 0.01%
78,755
– –
2015 Q4
15 quarters
AMED icon
63
DELISTED
Amedisys
AMED
$304K 0.01%
2,320
– –
2019 Q2
1 quarter
FLXN icon
64
DELISTED
Flexion Therapeutics, Inc.
FLXN
$296K 0.01%
21,630
– –
2018 Q1
6 quarters
VCEL icon
65
Vericel Corp
VCEL
$2.08B
$253K 0.01%
16,720
– –
2018 Q2
5 quarters
NBIX icon
66
Neurocrine Biosciences
NBIX
$14B
$247K 0.01%
2,740
– –
2019 Q2
1 quarter
LHCG
67
DELISTED
LHC Group LLC
LHCG
$246K 0.01%
2,166
– –
2018 Q3
4 quarters
INSP icon
68
Inspire Medical Systems
INSP
$2.03B
$239K 0.01%
+3,910
New +$257K
2019 Q3
0 quarters
BCRX icon
69
BioCryst Pharmaceuticals
BCRX
$2.02B
$215K 0.01%
+75,000
New +$233K
2019 Q3
0 quarters
UNH icon
70
UnitedHealth
UNH
$358B
$211K 0.01%
971
-140,930
-99% -$34M
2016 Q3
12 quarters
ESTA icon
71
Establishment Labs
ESTA
$1.82B
$189K 0.01%
10,000
– –
2018 Q3
4 quarters
VKTX icon
72
Viking Therapeutics
VKTX
$3.42B
$112K ﹤0.01%
16,260
– –
2018 Q3
4 quarters
CSLT
73
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$14K ﹤0.01%
10,229
– –
2018 Q2
5 quarters
ADVM icon
74
DELISTED
Adverum Biotechnologies
ADVM
– –
-2,224
Closed -$264K –
BMRN icon
75
CALL
BioMarin Pharmaceuticals
BMRN
$10.7B
– –
-100,000
Closed -$8.56M –
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2019 Portfolio in Review

As of Q3 2019, Redmile Group held 90 positions worth $2.99B, down 15% from $3.53B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q3 2019 filing shows 10 new, 29 increased, 22 reduced and 16 closed positions. Its largest new stake was Alexion Pharmaceuticals: 1,162,200 shares worth $114M. The largest sale was Array Biopharma Inc, an estimated $405M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Energy.

  • Redmile Group's largest Q3 2019 buy was Alexion Pharmaceuticals: 1,162,200 shares worth $114M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019, an estimated $75.7M increase.
  • Redmile Group's biggest Q3 2019 reduction was UnitedHealth, cutting an estimated $34M.
  • Redmile Group fully exited Array Biopharma Inc in Q3 2019, selling an estimated $405M.
  • Redmile Group's ten largest holdings make up 49% of its $2.99B portfolio in Q3 2019.
  • Redmile Group opened 10 new positions and closed 16 in Q3 2019.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $2.99B.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.